Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | ||
| Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | ||
| Afinitor | Everolimus | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Granulomatosis with polyangiitis and microscopic polyangiitis | List with clinical criteria and/or conditions | Complete | ||
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | ||
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete |
Last Updated : May 18, 2024